Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to protect kidneys in IgA nephropathy patients

NCT ID NCT06963827

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 8 times

Summary

This Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placebo over two 1-year cycles, with regular check-ups. The main goal is to see if the drug lowers proteinuria at 36 weeks compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mezagitamab (TAK-079) injections
What this could lead to
If it works, this could provide a new treatment option to slow kidney damage and delay kidney failure in people with IgA nephropathy.
What could go wrong
This is an early Phase 3 trial, so results are not yet proven. The drug may not significantly reduce proteinuria or preserve kidney function, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 347 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: To be eligible to participate in this trial, participants must meet all the following criteria: 1. Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial). 2. eGFR greater than (\>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m\^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial). 3. No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a). 4. The participant is aged ≥ 18 years or the local legal age as applicable. 5. The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form \[ICF\]) and any required privacy authorization before the initiation of any clinical trial procedures. 6. Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years. 7. Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy. 8. Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic. 9. Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin \[hCG\]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test). 10. Any one of the following (only applicable for participants in the open-label cohort): 1. Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR \>0.5 g/g or UPE \>0.5 g/d calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR \>30 mL/min/1.73m\^2 at screening based on the CKD-EPI formula. 2. UPCR \<0.8 g/g and UPE ≥0.75 and \<1.0 g/day, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR \> 30 mL/min/1.73m\^2 at screening based on the CKD-EPI formula. 3. UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL/min/1.73m\^2 at screening based on the CKD-EPI formula. * Exclusion Criteria: A participant who meets any of the following criteria will be excluded from participation in this trial: 1. Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease). 2. Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis. 3. Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF). 4. Diagnosis of nephrotic syndrome defined as 24-hour proteinuria \>3.5 g/day and hypoalbuminemia (\<3.0 grams per deciliter \[g/dL\]) with or without peripheral edema. 5. Renal or other organ transplantation prior to or expected during the clinical trial. 6. Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF. 7. If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply: 1. The last dose was received within 6 months before the signing of the ICF. 2. The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal. Note: Participants who have received the last dose of anti-CD20 treatment \>12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing. 8. Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules. 9. The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial. 10. Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1. 11. The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). 12. The participant has had any of the following types of infections within the specified timeframes where applicable: 1. Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1. 2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF. 3. Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF. 4. Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator. 5. For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP. 13. In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results. 14. In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment. 15. The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening. Note: Major surgery typically requires at least 1 night in the hospital. 16. History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ. 17. The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation. 18. The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) \<50% of predicted normal at screening. 19. The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP. 20. The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP. 21. The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP. 22. In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis impaired renal function disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    177 sites in 26 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • 4th Military Clinical hospital /Polyclinic SP ZOZ

    RECRUITING

    Wroclaw, 50-981, Poland

  • AOU Citta della Salute e della Scienza di Torino

    RECRUITING

    Torino, 10126, Italy

  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia

    RECRUITING

    Brescia, 25124, Italy

  • Academic Medical Research Institute

    RECRUITING

    Los Angeles, California, 90022, United States

  • Affiliated Hospital of Nantong University

    RECRUITING

    Nantong, Jiangsu, 226001, China

  • Ajou University Hospital-Primary Research Location

    RECRUITING

    Suwon, Gyeonggido, 16499, South Korea

  • Akershus University Hospital

    RECRUITING

    Lorenskog, Akershus, 1478, Norway

  • Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum)

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Az Ospedaliera Universitaria Policlinico G Martino

    RECRUITING

    Messina, 98122, Italy

  • Azienda Unita Sanitaria Locale Piacenza (AUSL) Ospedale "Guglielmo da Saliceto

    RECRUITING

    Piacenza, 29121, Italy

  • Beijing Tsinghua Changgung Hospital

    RECRUITING

    Changping, Beijing Municipality, 102218, China

  • Bioresearch Partners

    RECRUITING

    Miami, Florida, 33127, United States

  • Bioresearch Partners

    RECRUITING

    Pembroke Pines, Florida, 33029, United States

  • Birmingham Heartlands Hospital

    RECRUITING

    Birmingham, United Kingdom of Great Britain and Northern Ireland, United Kingdom

  • Brookview Hills Research Associates, LLC

    RECRUITING

    Winston-Salem, North Carolina, 27103, United States

  • CARE Institute - Boise Kidney

    RECRUITING

    Boise, Idaho, 83706, United States

  • CHU Bordeaux, CHU Pellegrin

    RECRUITING

    Bordeaux, 33076, France

  • CHU Limoges Service de Nephrology

    RECRUITING

    Limoges, 87042, France

  • CHU de Nantes

    RECRUITING

    Nantes, 44093, France

  • CTR Oakwater, LLC

    RECRUITING

    Orlando, Florida, 32806, United States

  • Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Lapeyronie

    RECRUITING

    Montpellier, 34090, France

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425AGC, Argentina

  • China Medical University Hospital

    RECRUITING

    Taichung, Taiwan

  • Clinica Privada Velez Sarsfield

    RECRUITING

    Córdoba, X5016, Argentina

  • Clinical Research Consultants a JCCT Company

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Core Research Group

    RECRUITING

    Milton, Queensland, Australia

  • DCR - El Paso

    RECRUITING

    El Paso, Texas, 79902, United States

  • DCR Columbus

    RECRUITING

    Columbus, Georgia, 31904, United States

  • DCR Edina

    RECRUITING

    Edina, Minnesota, 55435, United States

  • DCR Montgomery

    RECRUITING

    Montgomery, Alabama, 36117, United States

  • DCR San Antonio

    RECRUITING

    San Antonio, Texas, 78251, United States

  • Dallas Renal Group

    RECRUITING

    Dallas, Texas, 75230, United States

  • Dokkyo Medical University Saitama Medical Center

    RECRUITING

    Koshigaya-shi, Saitama, 343-8555, Japan

  • Eastern Health

    RECRUITING

    Box Hill, Victoria, 3128, Australia

  • Elixia MKC

    RECRUITING

    Pontiac, Michigan, 48341, United States

  • Elixia MNA

    RECRUITING

    City of Saint Peters, Missouri, 63376, United States

  • Erciyes University

    RECRUITING

    Kayseri, Melikgazi, 38039, Turkey (Türkiye)

  • Fakultni nemocnice Olomouc

    RECRUITING

    Olomouc, 779 00, Czechia

  • First Faculty of Medicine Charles University

    RECRUITING

    Prague, Czechia

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, 20100, Italy

  • Framingham Centro Medico

    RECRUITING

    Buenos Aires, La Plata, 1902, Argentina

  • Fujita Health University Hospital

    RECRUITING

    Toyoake-shi, Aichi-ken, 470-1192, Japan

  • Fukushima Medical University Hospital

    RECRUITING

    Fukushima, Fukushima, 960-1295, Japan

  • Fundacion Jimenez Diaz

    RECRUITING

    Madrid, 28040, Spain

  • Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi

    RECRUITING

    Şahinbey, Gaziantep, 27310, Turkey (Türkiye)

  • Guangdong General Hospital

    RECRUITING

    Guangzhou, Guangdong, 510080, China

  • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital

    RECRUITING

    London, Greater London, SE1 9RT, United Kingdom

  • Haukeland Universitetssjukehus

    RECRUITING

    Bergen, 5021, Norway

  • Hiroshima University Hospital

    RECRUITING

    Hiroshima, Hiroshima, 734-8551, Japan

  • Hokkaido University Hospital

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospital Britanico de Buenos Aires

    RECRUITING

    Ciudad Autonoma Buenos Aires, 1280, Argentina

  • Hospital Henri Mondor

    RECRUITING

    Créteil, Paris, 94000, France

  • Hospital Sultan Idris Shah Serdang (Hospital Serdang)

    RECRUITING

    Kajang, Selangor, 43000, Malaysia

  • Hospital Taiping

    RECRUITING

    Taiping, Perak, 34000, Malaysia

  • Hospital Tengku Ampuan Afzan

    RECRUITING

    Kuantan, Pahang, 25100, Malaysia

  • Hospital Tenon

    RECRUITING

    Paris, 75020, France

  • Hospital Universitari Germans Trias i Pujol

    RECRUITING

    Badalona, Barcelona, 8915, Spain

  • Hospital Universitari Vall d'Hebron

    RECRUITING

    Barcelona, 8035, Spain

  • Hospital Universitario Virgen del Rocio - PPDS

    RECRUITING

    Seville, 41013, Spain

  • Hospital Universitario de Cruces

    RECRUITING

    Barakaldo, Bizkaia, 48903, Spain

  • Hospital del Mar

    RECRUITING

    Barcelona, 8003, Spain

  • Houston Methodist Research Institute - Department of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

  • Hull University Teaching Hospitals NHS Trust

    RECRUITING

    Hull, United Kingdom

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    RECRUITING

    Bologna, 40138, Italy

  • IRCCS Ospedale Policlinico San Martino

    RECRUITING

    Genoa, 16132, Italy

  • Indywidualna Specjalistyczna Praktyka Lekarska

    RECRUITING

    Lodz, Poland

  • Ingham Nephrology & Hypertension, P.C.

    RECRUITING

    Lansing, Michigan, 48911, United States

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi

    RECRUITING

    Fatih, Istanbul, 34098, Turkey (Türkiye)

  • Istituto Maugeri IRCCS Pavia

    RECRUITING

    Pavia, 27100, Italy

  • Japan Community Health care Organization Sendai Hospital

    RECRUITING

    Sendai, Miyagi, 981-3281, Japan

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

    RECRUITING

    Nagoya, Aichi-ken, 466-8650, Japan

  • Johannes Kepler Universitat Linz, Universitatsklinik fur Innere 2

    RECRUITING

    Linz, 4040, Austria

  • Juntendo University Hospital

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Avsar Mah

    RECRUITING

    Kahramanmaraş, Onikisubat, 46040, Turkey (Türkiye)

  • Kaohsiung Medical University - Chung-Ho Memorial Hospital

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Kasugai Municipal Hospital

    RECRUITING

    Kasugai-Shi, Aichi-ken, 486-8510, Japan

  • Kent & Canterbury Hospital, Canterbury

    RECRUITING

    Canterbury, CT1 3PA, United Kingdom

  • King's College Hospital

    RECRUITING

    London, WC2R 2LS, United Kingdom

  • Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi

    RECRUITING

    Kocaeli, Turkey (Türkiye)

  • Kyushu University Hospital

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • Lancashire Teaching Hospital NHS Foundation Trust

    RECRUITING

    Preston, PR29HT, United Kingdom

  • Leicester General Hospital

    RECRUITING

    Leicester, United Kingdom

  • Leids Universitair Medisch Center

    RECRUITING

    Leiden, 2333 ZA, Netherlands

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A5A5, Canada

  • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka

    RECRUITING

    Osaka, Osaka, 530-8480, Japan

  • Medizinische Universitat Wien (Medical University of Vienna - Austria)

    RECRUITING

    Vienna, 1090, Austria

  • Monash Heath - Monash University - Monash Medical Centre

    RECRUITING

    Clayton, Victoria, Australia

  • Nara Medical University Hospital

    RECRUITING

    Kashihara-shi, Nara, 634-8522, Japan

  • Nara Prefecture General Medical Center

    RECRUITING

    Nara, Nara, 630-8581, Japan

  • National Hospital Organization Chiba Medical Center Chibahigashi National Hospital

    RECRUITING

    Chiba, Chiba, 260-8712, Japan

  • National Taiwan University Hospital

    RECRUITING

    Zhongzheng, 100, Taiwan

  • National University Hospital

    RECRUITING

    Singapore, Singapore

  • Necmettin Erbakan University

    RECRUITING

    Konya, Selcuklu, 42280, Turkey (Türkiye)

  • Nemocnice AGEL Novy Jicin a.s

    RECRUITING

    Nový Jičín, Moravskoslezsk Kraj, 741 01, Czechia

  • Nephrology Associates of Houston PLLC

    RECRUITING

    Katy, Texas, 77450, United States

  • Northern General Hospital

    RECRUITING

    Sheffield, United Kingdom

  • Northwest Louisiana Nephrology

    RECRUITING

    Shreveport, Louisiana, 71101, United States

  • Nottingham University Hospitals NHS Trust - City Hospital

    RECRUITING

    Nottingham, United Kingdom

  • Nowy Szpital Sp Zo.o

    RECRUITING

    Gmina Świecie, 86-100, Poland

  • Oita University Hospital

    RECRUITING

    Yufu-shi, Oita Prefecture, 879-5593, Japan

  • Panoramic Health - Clinical Renal Associates, Ltd.

    RECRUITING

    Media, Pennsylvania, 19063, United States

  • Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)

    RECRUITING

    Jacksonville, Florida, 32250, United States

  • Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)

    RECRUITING

    Melbourne, Florida, 32901, United States

  • Panoramic Health - Florida Kidney Physicians, LLC (Tampa)

    RECRUITING

    Riverview, Florida, 03578, United States

  • Panoramic Health - Kidney and Hypertension Center

    RECRUITING

    Cincinnati, Ohio, 45212, United States

  • Panoramic Health - Lake Michigan Nephrology, PLC

    RECRUITING

    Saint Joseph, Michigan, 49085, United States

  • Panoramic Health - Nephrology Associates, Inc.

    RECRUITING

    East Providence, Rhode Island, 02914, United States

  • Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates

    RECRUITING

    Rockford, Illinois, 61107, United States

  • Panoramic Health - Southeast Kidney Associates

    RECRUITING

    East Point, Georgia, 30344, United States

  • Panoramic Health - Southwest Kidney Institute, PLC

    RECRUITING

    Surprise, Arizona, 85374, United States

  • Panoramic Health - Virginia Nephrology Group

    RECRUITING

    Arlington, Virginia, 22205, United States

  • Panoramic Health - West Coast Kidney Institute (Fremont)

    RECRUITING

    Fremont, California, 94538, United States

  • Peking University First Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

  • Peking University Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, 518000, China

  • Provecta Research Network

    RECRUITING

    Houston, Texas, 77054, United States

  • Radboud Universitair Medisch Centrum

    RECRUITING

    Nijmegen, 6525 GA, Netherlands

  • Renal Medicine Associates - Frenova F1

    RECRUITING

    Albuquerque, New Mexico, 87109, United States

  • Renal Medicine Linkoping University/ Linkoping University Hospital

    RECRUITING

    Linköping, Sweden

  • Ruijin Hospital of Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

  • SCM Sp. z o.o.

    RECRUITING

    Krakow, 31-559, Poland

  • Semmelweis Egyetem - Belgyogyaszati es Onkologiai Klinika (I.sz. Belgyogyaszati Klinika)

    RECRUITING

    Budapest, 1083, Hungary

  • Seoul National University Boramae Medical Center

    RECRUITING

    Seoul, 7061, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, Seongnam, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 3080, South Korea

  • Shandong University - Qilu Hospital

    RECRUITING

    Jinan, Shandong, 250012, China

  • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

  • Sheldon M. Chumir Health Centre

    RECRUITING

    Calgary, Alberta, T2R 0X7, Canada

  • Shonan Kamakura General Hospital

    RECRUITING

    Kamakura-shi, Kanagawa, 247-8533, Japan

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610072, China

  • Singapore General Hospital

    RECRUITING

    Singapore, 169608, Singapore

  • Sint Antonius ziekenhuis Utrecht/Nieuwegein

    RECRUITING

    Nieuwegein, 3435CM, Netherlands

  • South Florida Research Institute

    RECRUITING

    Lauderdale Lakes, Florida, 33313-1607, United States

  • South Western Sydney Local Health District - University of New South Wales - Liverpool Hospital

    RECRUITING

    Liverpool, New South Wales, Australia

  • St George's University Hospitals NHS Foundation Trust

    RECRUITING

    London, SW17 0QT, United Kingdom

  • Stavanger Universitetssjukehus - Helse Stavanger HF

    RECRUITING

    Stavanger, Norway

  • Sun Research Institute

    RECRUITING

    San Antonio, Texas, 78215, United States

  • Sunnybrook Health Sciences Centre

    RECRUITING

    Toronto, Ontario, M4G 3E8, Canada

  • Sunway Medical Centre (SMC)

    RECRUITING

    Subang Jaya, Selangor, 47500, Malaysia

  • Sykehuset I Vestfold

    RECRUITING

    Tønsberg, Vestfold, Norway

  • Sykehuset Ostfold

    RECRUITING

    Grålum, 1714, Norway

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 40705, Taiwan

  • Taipei Medical University Shuang Ho Hospital

    RECRUITING

    New Taipei City, Taiwan

  • Tan Tock Seng Hospital

    RECRUITING

    Singapore, 308433, Singapore

  • The First Affiliated Hospital of Baotou Medical College

    RECRUITING

    Baotou, Inner Mongolia, 14010, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Ningbo University

    RECRUITING

    Ningbo, Zhejiang, 315010, China

  • The Second Affiliated Hospital, Zhejiang University, School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • The Second People's Hospital of Yibin

    RECRUITING

    Yibin, Sichuan, 644099, China

  • The Third Xiangya Hospital of Central South University Yuelu District

    RECRUITING

    Changsha, Hunan, 410013, China

  • The University of Hong Kong - Department of Medicine

    RECRUITING

    Hong Kong, Hong Kong Island, Hong Kong

  • Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Tokyo Medical University Hospital

    RECRUITING

    Shinjuku-Ku, Tokyo, 160-0023, Japan

  • Toranomon Hospital Kajigaya

    RECRUITING

    Kawasaki-shi, Kanagawa, 213-8587, Japan

  • Turgut Ozal Medical Center

    RECRUITING

    Malatya, Battalgazi, 44280, Turkey (Türkiye)

  • UAB Nephrology Research Clinic at Paula Building

    RECRUITING

    Birmingham, Alabama, 35233-2110, United States

  • UMC Utrecht

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • Uniklinik RWTH Aachen

    RECRUITING

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Universidad de Navarra - Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Universidad de Navarra - Clinica Universidad de Navarra

    RECRUITING

    Madrid, 28027, Spain

  • Universitaetsklinikum Jena

    RECRUITING

    Jena, Thuringia, 7747, Germany

  • Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz

    RECRUITING

    Mainz, 55131, Germany

  • Universitetssykehuset I Trondheim - St. Olavs Hospital - Nevroklinikken

    RECRUITING

    Trondheim, 7030, Norway

  • Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))

    RECRUITING

    Kuala Lumpur, Kuala Lumpur, 56000, Malaysia

  • Universiti Malaya Medical Centre (UMMC)

    RECRUITING

    Kuala Lumpur, 50603, Malaysia

  • University Clinical Centre Maribor

    RECRUITING

    Maribor, Slovenia

  • University Hospital Zurich

    RECRUITING

    Zurich, 8091, Switzerland

  • University Medical Centre Ljubljana

    RECRUITING

    Ljubljana, 1000, Slovenia

  • University of California Irvine

    RECRUITING

    Orange, California, 92868-3201, United States

  • University of Yamanashi Hospital

    RECRUITING

    Chuo-shi, Yamanashi, 409-3898, Japan

  • Utah Kidney Research Institute

    RECRUITING

    Salt Lake City, Utah, 84115, United States

  • West China Hospital Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610000, China

  • West Virginia University

    RECRUITING

    Morgantown, West Virginia, 26506, United States

  • Western Health Sunshine Hospital

    RECRUITING

    St Albans, Victoria, 3021, Australia

  • Wuxi People's Hospital

    RECRUITING

    Wuxi, Jiangsu, 214023, China

  • Yokohama City University Hospital

    RECRUITING

    Yokohama, Kanagawa, 236-0004, Japan

  • Zhongda Hospital Southeast University

    RECRUITING

    Nanjing, Jiangsu, 210009, China

  • Zhongshan Hospital Xiamen University

    RECRUITING

    Xiamen, Fujian, 361004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.